Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study.
Saved in:
| Title: | Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study. |
|---|---|
| Authors: | Chanchlani, Neil1 (AUTHOR) neilchanchlani@nhs.net, Lin, Simeng1 (AUTHOR), Auth, Marcus K.2 (AUTHOR), Lee, Chai Leng2 (AUTHOR), Robbins, Helena3 (AUTHOR), Looi, Shi3 (AUTHOR), Murugesan, Senthil V.4 (AUTHOR), Riley, Tom4 (AUTHOR), Preston, Cathryn5 (AUTHOR), Stephenson, Sophie5 (AUTHOR), Cardozo, Wendy5 (AUTHOR), Sonwalkar, Sunil A.6 (AUTHOR), Allah‐Ditta, Mohammed6 (AUTHOR), Mansfield, Lynne6 (AUTHOR), Durai, Dharmaraj7 (AUTHOR), Baker, Mark7 (AUTHOR), London, Ian8 (AUTHOR), London, Emily8 (AUTHOR), Gupta, Sanjay9 (AUTHOR), Di Mambro, Alex10 (AUTHOR) |
| Source: | Alimentary Pharmacology & Therapeutics. Oct2022, Vol. 56 Issue 8, p1250-1263. 14p. 1 Diagram, 2 Charts, 4 Graphs. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 02692813 |
|---|---|
| DOI: | 10.1111/apt.17170 |
